OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.

OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.

Ms. Healy joined Photocure in March 2025 to lead the European Organization. Her extensive international experience in the medical device field covers sales, marketing, general management and functional leadership. Over the past 30 years she has worked for three major medical device organizations; St Jude Medical, CR Bard and over 20 years for Boston Scientific.

OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.

Ms. Healy joined Photocure in March 2025 to lead the European Organization. Her extensive international experience in the medical device field covers sales, marketing, general management and functional leadership. Over the past 30 years she has worked for three major medical device organizations; St Jude Medical, CR Bard and over 20 years for Boston Scientific.

OSLO, Norway, March 24, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in Madrid, Spain, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on recurrence risk and ability to help urologists make  the best bladder cancer management choices for their patients.

The EAU annual meeting is one of the largest international meetings in the urology calendar, showcasing the latest and most relevant clinical and scientific advancements in this area of patient care. This year's event was held on March 21-24, 2025, and attracted urologists from all over the world. Photocure participated with its Hexvix® product designed for better detection and resection of bladder tumors under the theme that "Seeing is believing". As in the past two years, Photocure will make 2025 EAU bladder cancer session highlights available to healthcare professionals after the event, by means of video interviews with the presenters of these sessions at the Photocure booth B28. This successful initiative is once again supported by two of the leading names in Bladder Cancer in Europe, Prof. M. Rouprêt, APHP, Sorbonne University Paris, France and Prof. P. Gontero, Division of Urology, University of Studies of Torino, Italy.

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess if blue light cystoscopy (BLC®) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurrence compared to white light cystoscopy (WLC) use alone in a predominantly high-risk NMIBC patient cohort. These results are in line with prior results from multiple randomized controlled clinical trials.

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess if blue light cystoscopy (BLC®) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurrence compared to white light cystoscopy (WLC) use alone in a predominantly high-risk NMIBC patient cohort. These results are in line with prior results from multiple randomized controlled clinical trials.

OSLO, Norway, Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in milestones this year.

OSLO, Norway, Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in milestones this year.

OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces an update regarding its ongoing collaboration with Richard Wolf to develop a high-definition flexible blue light cystoscope for global commercialization. The development process for an optimized solution is progressing on plan, with an interim solution now available to centers in all countries where System blue and other components are cleared.

A collaborative R&D process such as this sometimes yields new discoveries. An interim solution for blue light flexible cystoscopy combining existing equipment parts was born from that process. The interim solution makes the Richard Wolf System blue platform compatible with one of its reusable flexible scopes.

OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview, bladder cancer management decisions can be made more appropriately.